• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "Qiangguyin inhibited fat accumulation in OVX mice through the p38 MAPK signaling pathway to achieve anti-osteoporosis effects"[Biomed. Pharmacother. 158 (2023) 114122].

作者信息

Wen Jingyuan, Bao Zhengsheng, Li Lunxin, Liu Yingquan, Wei Bing, Ye Xiaoang, Xu Huihui, Cui Longkang, Li Xuefei, Shen Gaobo, Fang Yuan, Zeng Hanbing, Shen Zhe, Guo Enping, Jin Hongting, Wu Lianguo

机构信息

The Second Clinical College, Zhejiang Chinese Medical University, Hangzhou, China; The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.

The First Clinical College, Zhejiang Chinese Medical University, Hangzhou, China.

出版信息

Biomed Pharmacother. 2024 Jul;176:116914. doi: 10.1016/j.biopha.2024.116914. Epub 2024 Jun 8.

DOI:10.1016/j.biopha.2024.116914
PMID:38853031
Abstract
摘要

相似文献

1
Corrigendum to "Qiangguyin inhibited fat accumulation in OVX mice through the p38 MAPK signaling pathway to achieve anti-osteoporosis effects"[Biomed. Pharmacother. 158 (2023) 114122].《强骨饮通过p38丝裂原活化蛋白激酶信号通路抑制去卵巢小鼠脂肪堆积以实现抗骨质疏松作用》的勘误[《生物医学与药物治疗》158 (2023) 114122]
Biomed Pharmacother. 2024 Jul;176:116914. doi: 10.1016/j.biopha.2024.116914. Epub 2024 Jun 8.
2
Qiangguyin inhibited fat accumulation in OVX mice through the p38 MAPK signaling pathway to achieve anti-osteoporosis effects.强骨饮通过 p38 MAPK 信号通路抑制去卵巢小鼠的脂肪堆积，从而达到抗骨质疏松的作用。
Biomed Pharmacother. 2023 Feb;158:114122. doi: 10.1016/j.biopha.2022.114122. Epub 2022 Dec 23.
3
Corrigendum to "Amiodarone induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts" [Biomed. Pharmacother. 115 (2019) 108889].《胺碘酮通过ERK1/2和p38 MAPK信号通路诱导成纤维细胞增殖和肌成纤维细胞分化》[《生物医学与药物治疗》115卷（2019年）108889页]的勘误
Biomed Pharmacother. 2019 Oct;118:109085. doi: 10.1016/j.biopha.2019.109085. Epub 2019 Jun 6.
4
Corrigendum to 'Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway' [Biomed. Pharmacother. 90 (2017) 437-445].《米非司酮通过调节RAS/RAF/MEK/MAPK信号通路抑制非小细胞肺癌的增殖和转移》的勘误[《生物医学与药物治疗》90(2017)437 - 445]
Biomed Pharmacother. 2018 Feb;98:925-926. doi: 10.1016/j.biopha.2018.01.091.
5
Corrigendum to "Secretory products of DPSC mitigate inflammatory effects in microglial cells by targeting MAPK pathway" Biomed. Pharmacother. 170(2024) 115971.《牙髓干细胞的分泌产物通过靶向丝裂原活化蛋白激酶途径减轻小胶质细胞的炎症反应》的勘误 生物医学与药物治疗 170(2024) 115971
Biomed Pharmacother. 2024 Aug;177:117061. doi: 10.1016/j.biopha.2024.117061. Epub 2024 Jul 2.
6
Corrigendum to "Inhibition of p38 and ERK1/2 pathways by Sparstolonin B suppresses inflammation-induced melanoma metastasis" [Biomed. Pharmacother. 98 (2018) 382-389].《斯巴司他宁B对p38和ERK1/2通路的抑制作用抑制炎症诱导的黑色素瘤转移》勘误[《生物医学与药物治疗》98 (2018) 382 - 389]
Biomed Pharmacother. 2023 Nov;167:115616. doi: 10.1016/j.biopha.2023.115616. Epub 2023 Oct 2.
7
Corrigendum to "ZSCAN16 promotes proliferation, migration and invasion of bladder cancer via regulating NF-kB, AKT, mTOR, P38 and other genes" [Biomed. Pharmacother. 126 (2020) 110066].《“ZSCAN16通过调节NF-kB、AKT、mTOR、P38等基因促进膀胱癌的增殖、迁移和侵袭”的勘误》[《生物医学与药物治疗》126卷（2020年）第110066页]
Biomed Pharmacother. 2020 Oct;130:110858. doi: 10.1016/j.biopha.2020.110858. Epub 2020 Oct 11.
8
The effect of QiangGuYin on osteoporosis through the AKT/mTOR/autophagy signaling pathway mediated by CKIP-1.强骨饮通过 CKIP-1 介导的 AKT/mTOR/自噬信号通路对骨质疏松症的作用。
Aging (Albany NY). 2022 Jan 24;14(2):892-906. doi: 10.18632/aging.203848.
9
Corrigendum to "Suppression of abdominal fat and anti-hyperlipidemic potential of Emblica officinalis: Upregulation of PPARs and identification of active moiety" Biomed. Pharmacother. 108 (2018) 1274-1281.《余甘子抑制腹部脂肪和抗高血脂的潜力：过氧化物酶体增殖物激活受体的上调及活性成分鉴定》的勘误，发表于《生物医学与药物治疗》108卷（2018年）第1274 - 1281页。
Biomed Pharmacother. 2024 Aug;177:116945. doi: 10.1016/j.biopha.2024.116945. Epub 2024 Jun 19.
10
Retraction notice to "Corrigendum to 'mPEG-b-P(Glu-co-Phe) nanoparticles increase gastric retention time and gastric ulcer treatment efficacy of 20(S)-ginsenoside Rg3' [Biomed. Pharmacother. 146 (2022) 112608]" [Biomed. Pharmacother. 152 (2022) 113213].对“《‘mPEG-b-P(Glu-co-Phe)纳米颗粒增加20(S)-人参皂苷Rg3的胃滞留时间和胃溃疡治疗效果’的勘误》[生物医学与药物治疗学146 (2022) 112608]”[生物医学与药物治疗学152 (2022) 113213]的撤回通知。
Biomed Pharmacother. 2023 Apr;160:114280. doi: 10.1016/j.biopha.2023.114280. Epub 2023 Jan 31.